Last reviewed · How we verify
Benzamycin (BENZOYL PEROXIDE)
Benzamycin (generic name: BENZOYL PEROXIDE) is a benzoyl peroxide Small molecule drug developed by Mayne Pharma. It is currently FDA-approved (first approved 1984) for Acne vulgaris, Atopic dermatitis, Contact dermatitis.
Benzamycin is a small molecule medication that releases active oxygen. It is used to treat osteomyelitis, typically in combination with intravenous antibiotics, as part of a treatment regimen.
At a glance
| Generic name | BENZOYL PEROXIDE |
|---|---|
| Sponsor | Mayne Pharma |
| Drug class | benzoyl peroxide |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 1984 |
Approved indications
- Acne vulgaris
- Atopic dermatitis
- Contact dermatitis
- Eruption of skin
- Granuloma annulare
- Pruritus ani
- Pruritus of genital organs
- Seborrheic dermatitis
Common side effects
- Dryness
- Urticarial reaction
- Skin irritation
- Peeling
- Itching
- Burning sensation
- Erythema
- Inflammation of the face
- Eye inflammation
- Nasal inflammation
- Eye irritation
- Skin discoloration
Key clinical trials
- Burn Pit Exposure in Veterans: A Cancer Screening Pilot Study at the Inova Saville Cancer Screening & Prevention Center (NA)
- Topical 5% Spironolactone Gel Versus 0.1% Adapalene Gel for Acne Vulgaris: A Randomized Split-Face Study (PHASE2)
- Inova Cardiogenic Shock Registry (INOVA SHOCK)
- 1% Clascoterone Cream for the Treatment Acne Vulgaris (PHASE3)
- Occupational Cancer Screening in Firefighters: A Pilot Study Within the Inova Health System (NA)
- Evaluation of Topical Dutasteride as a Potential New Therapy for Facial Acne Vulgaris Versus the Triple Combination Therapy (Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel) (NA)
- Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Triple Combination Gel in Canadian Patients With Acne Vulgaris
- Auricular Acupressure Combined With Adapalene for the Treatment of Acne Vulgaris (NA)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Benzamycin CI brief — competitive landscape report
- Benzamycin updates RSS · CI watch RSS
- Mayne Pharma portfolio CI
Frequently asked questions about Benzamycin
What is Benzamycin?
What is Benzamycin used for?
Who makes Benzamycin?
What is the generic name of Benzamycin?
What drug class is Benzamycin in?
When was Benzamycin approved?
What development phase is Benzamycin in?
What are the side effects of Benzamycin?
Related
- Drug class: All benzoyl peroxide drugs
- Manufacturer: Mayne Pharma — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Acne vulgaris
- Indication: Drugs for Atopic dermatitis
- Indication: Drugs for Contact dermatitis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing